Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
about
Anti-HBV Drugs: Progress, Unmet Needs, and New HopeHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedDetection and analysis of resistance mutations of hepatitis B virusLamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Review of hepatitis B therapeutics.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Surgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil.Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective studyHBV and HCV therapy.The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus InfectionMeta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.Tenofovir for the treatment of hepatitis B virus.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.Drug safety evaluation of adefovir in HBV infection.Molecular diagnosis and treatment of drug-resistant hepatitis B virus.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs.Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.JSH Guidelines for the Management of Hepatitis B Virus Infection.Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.Sequential analysis of amino acid substitutions with hepatitis B virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing.Prevention and management of drug resistant hepatitis B virus infections.rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on
P2860
Q26782742-5E586C58-D700-4DAB-9479-A20E9459BB3AQ28076703-BFCA478A-0AD6-4B2E-9665-76F6DF10ABD6Q28266666-F07C8258-60F4-4BBE-ACE5-3C0AD58692BDQ33985364-737097D7-9499-4C43-A327-F9BFEF7821DFQ34045308-21E4C4EC-B5F6-48C2-B3E3-A499A76CF907Q34296410-2918BF17-004F-47B5-BACA-3A89892F873DQ34339608-328B41CB-3AA0-42E2-9E33-DC533C60A3C7Q34390303-9347122A-4833-41C1-BC49-79F134CBE0EAQ34405008-A9668329-148D-49E1-87F7-D124C639CE55Q34471072-352B96C0-EF8A-498C-8419-46AD8DC3A36EQ34809263-882E4B5B-215F-4C59-AB7D-3A3BDABF9622Q34974141-CA5F1478-0EC5-4FCE-B10B-42D573B1FA8AQ35259824-F6E53B4E-5695-42E7-B01E-F453F908BBA5Q36154994-5A16FB54-3590-4369-AEF8-4EE5BF383585Q36561590-61FC4A1C-51B7-4089-9C52-6C49B0B1C98EQ37196931-A5542AB0-6150-406E-B07E-F24B59EFD0FBQ37393925-FC5F1B81-3D7D-4005-8564-5F26BBE935D8Q37605886-EBE96573-7735-4476-9F73-19842863EF68Q37620354-EB7B0613-82BE-432D-B10D-1809F05FF6E0Q37768591-1E423D61-0109-4FA5-B1FB-365DBB3C873CQ37800919-D9DC0C93-69A0-43FD-ACF7-F29226BAD517Q37889298-AE76D992-642D-4CE3-9D4A-011E69DA854FQ38219020-68A1D03C-6DCC-49F4-81F6-497E9471CDD8Q38655765-708EA1EB-A23C-46C8-9861-55D270BE0820Q39174722-6218AF65-072A-4B08-AB2E-28B79CE506E0Q40335324-D2CBC9EE-AC69-4862-BE68-1C65B4FF232FQ42199423-2C775320-3354-416A-A672-382B07DA3698Q42244740-A48E41BA-47DE-4947-8DC1-07F6D42A0CDDQ42278002-0AC3CADC-645F-4F26-A78B-92459931A7BAQ43950558-DAFE53B6-75A7-49CA-A798-690450405DA3Q44519264-518CA1C6-FCC8-4EDB-B779-1040328AE781Q45351100-2F5056DD-2C4E-4318-8211-6686E35A28D7Q45356906-8DE8661F-DB39-4B58-ADFF-6B9CA8F6CF8AQ45364825-8898AF1E-7D55-4E4A-8CAC-1206D2FE7920Q45368315-F997133A-3393-4148-B9A5-DF82016B88CBQ45377033-7EE27257-E6D6-4AE3-822C-861541CB527BQ51191468-CC460BF7-946E-46B5-AF62-CDAAE19C2CF8Q56982718-FF0045C4-9C53-40C7-9EC3-EE149A67A72F
P2860
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@en
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@nl
type
label
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@en
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@nl
prefLabel
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@en
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@nl
P2093
P1476
Low risk of adefovir resistanc ...... n therapy: two-year follow-up.
@en
P2093
Fumitaka Suzuki
Hiromi Yatsuji
Hiromitsu Kumada
Hitomi Sezaki
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Norio Akuta
Sachiyo Watahiki
Satomi Iwasaki
P304
P356
10.1016/J.JHEP.2008.02.019
P577
2008-04-01T00:00:00Z